discovery studio® cdocker protocol (Accelrys)
90
Structured Review
Accelrys
discovery studio® cdocker protocol
Discovery Studio® Cdocker Protocol, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio%C2%AE+cdocker+protocol/discovery+studio+2017+cdocker+protocol/pm40346763-677-5-15
Average 90 stars, based on 1 article reviews
Discovery Studio® Cdocker Protocol, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studio%C2%AE+cdocker+protocol/discovery+studio+2017+cdocker+protocol/pm40346763-677-5-15
Average 90 stars, based on 1 article reviews
discovery studio® cdocker protocol - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Activity Assay:Article Title: Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Article Snippet: Article Title: Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. Article Snippet: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor survival rates in adults, posing a significant economic burden.. FMS‐like tyrosine kinase 3 (FLT3) mutations are linked to poor prognosis in AML and resistance to clinically approved FLT3 inhibitors.. Previously, we reported a novel benzimidazole‐based FLT3 inhibitor, 4ACP, with nanomolar activities against FLT3‐ITD and FLT3‐TKD mutants, showing selective cytotoxicity against FLT3‐ITD AML cell lines. Inhibition:Article Title: Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Article Snippet: Article Title: Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. Article Snippet: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor survival rates in adults, posing a significant economic burden.. FMS‐like tyrosine kinase 3 (FLT3) mutations are linked to poor prognosis in AML and resistance to clinically approved FLT3 inhibitors.. Previously, we reported a novel benzimidazole‐based FLT3 inhibitor, 4ACP, with nanomolar activities against FLT3‐ITD and FLT3‐TKD mutants, showing selective cytotoxicity against FLT3‐ITD AML cell lines. |